Bank of Nova Scotia closed 7.2% short of its 52-week high of C$80.14, which the company reached on December 2nd.
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares.
TORONTO, Jan. 31, 2025 /CNW/ - Scotiabank will announce its first quarter results on Tuesday, February 25, 2025. Financial results will be issued in a press release at approximately 5:30 a.m. ET on ...
In a report released today, Maher Yaghi from Scotiabank maintained a Buy rating on Comcast (CMCSA – Research Report), with a price target of ...
Shares of Bank of Nova Scotia BNS inched 0.21% higher to C$75.07 Thursday, in what proved to be an all-around favorable trading session for the Canadian market, with the S&P/TSX Composite Index GSPTSE ...
Scotiabank announced today that it is decreasing its Canadian dollar prime lending rate to 5.20 per cent from 5.45 per cent, effective January 30, 2025.
The Toronto Sceptres are selling out the city's largest venues, and the WNBA's Toronto Tempo are ready to launch. There's a ...
"Maybe Ben Bernanke can help out Mr. Trump with a lesson on the various factors leading up to the Great Depression," ...
Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...